Evidence map›Paper›PMID 33088699›Full record

ReviewJournal of bone oncology2020

Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis.

Evgenia Papakonstantinou, Alexandros Stamatopoulos, Dimitrios I Athanasiadis, Efstathios Kenanidis, Michael Potoupnis, Anna-Bettina Haidich, Eleftherios Tsiridis

Open access · goldAbstract readReview
In one paragraph

Review in Journal of bone oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. [Polyphyllin VII inhibits osteosarcoma xenograft growth in mice by inducing ferroptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Osteosarcoma: current insights and advances.Exploration of targeted anti-tumor therapy · 2025
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Evgenia PapakonstantinouPediatric Oncology Department, Hippokration Hospital, Thessaloniki, Greece.
Alexandros StamatopoulosAcademic Orthopaedic Department, Papageorgiou General Hospital, Aristotle University Medical School, Thessaloniki, Greece.
Dimitrios I AthanasiadisDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA.
Efstathios KenanidisAcademic Orthopaedic Department, Papageorgiou General Hospital, Aristotle University Medical School, Thessaloniki, Greece.
Michael PotoupnisAcademic Orthopaedic Department, Papageorgiou General Hospital, Aristotle University Medical School, Thessaloniki, Greece.
Anna-Bettina HaidichDepartment of Hygiene, Social-Preventive Medicine & Medical Statistics, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Eleftherios TsiridisAcademic Orthopaedic Department, Papageorgiou General Hospital, Aristotle University Medical School, Thessaloniki, Greece.
Aristotle University of Thessaloniki · GRHippocration General Hospital · GRIndiana University School of Medicine

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma is the most common primary bone sarcoma. Currently, the main treatment option for high-grade osteosarcomas is neoadjuvant chemotherapy, followed by surgical resection of the lesion and adjuvant chemotherapy. Limb salvage surgery (LSS) and amputation are the main surgical techniques; however, controversy still exists concerning the best surgical method. Our meta-analysis compared the effectiveness of LSS and amputation combined with neoadjuvant chemotherapy in patients with limb osteosarcoma, in terms of 5-year overall survival (OS), 5-year disease-free survival (DFS) and local recurrence rate.

methodsFollowing the established methodology of PRISMA guidelines, a literature search was conducted in PubMed, Cochrane, Google Scholar from 1975 until January 2020. Two independent reviewers evaluated the study quality based on the Newcastle-Ottawa scale. Odds ratio and 95% confidence interval of the OS, DFS and local recurrence rate were calculated.

resultsThirteen studies were finally included with a total of 2884 patients; 1986 patients undergone LSS and 898 amputations. Five-year overall survival was almost 2-fold in patients treated with LSS than those treated with amputation (OR: 1.99; 95% CI: 1.35-2.93; I

conclusionOur study demonstrated that in patients with limb osteosarcoma treated with neoadjuvant chemotherapy, LSS is associated with a higher 5-year overall survival and the odds of local recurrence may be increased but these results should be interpreted with caution due to high heterogeneity.

Indexed as

AJCC, American Joint Cancer CommitteeAmputationASCO, American Society of Clinical OncologyCATS, Computed Assisted Tumor SurgeryCCG, Children’s Cancer GroupCI, Confidence IntervalCOSS, Cooperative Osteosarcoma Study GroupCT, Computed TomographyDFS, Disease Free SurvivalFNA, Fine Needle AspirationLimb-salvage surgeryLSS, Limb Salvage SurgeryMAP, MTX, Adriamycin, CisplatinMRI, Magnetic Resonance ImagingMSKCC, Memorial Sloan Kattering Cancer CenterMSTS, Musculoskeletal Tumor SocietyNCCN, National Comprehensive Cancer NetworkNeoadjuvant chemotherapyNOS, Newcastle–Ottawa scaleNPCR, National Program of Cancer RegistriesOR, Odds RatioOS, Overall SurvivalOsteosarcomaPET, Positron Emission TomographyPOG, Pediatric Oncology GroupRCT, Randomized Controlled TrialsRev-Man, Review ManagerSEER, Surveillance, Epidemiology, and End ResultsSIOP, International Society of Paediatric OncologyTc-MDP, Methylene diphosphonate with technetium-99mVICC, Vanderbilt-Ingram Cancer Center

Identifiers

PMID33088699
PMCPMC7567946
OpenAlexW3087567806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.